Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org
-- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Saturday, January 8, 2011
Thursday, January 6, 2011
The National MS Society
and MS Learn Online present...
A new Feature Presentation:
A video webcast that explores...
Women who have multiple sclerosis(MS) are more likely to have a gene associated with multiple sclerosis than men with the disease and it is this gene region where environment interacts with the genetics, according to a study published in the January 5, 2011, online issue ofNeurology®, the medical journal of the American Academy of Neurology.
Research has shown that the number of people diagnosed with MS has been rising, and the rate has been rising faster for women than for men.
Wednesday, January 5, 2011
(AP:THE WOODLANDS, Texas) Opexa Therapeutics Inc. said Wednesday it is preparing to start a late-stage clinical trial of Tovaxin, a multiple sclerosis treatment that uses cells from the patient's body to fight the disease.
The company said it met with the Food and Drug Administration twice after finishing midstage testing of Tovaxin, and now knows what the FDA expects from a late-stage study. That makes it more likely the FDA will approve the drug if the trial is successful. Opexa did not disclose specifics about the trial, but said its plans are partly based on data showing that Tovaxin was effective in reducing MS relapses patients who had not been treated with any other therapies except steroids.
Opexa and the FDA discussed the design of the trial, the types of patients to be selected, and improvements to the manufacturing process for the drug.
Tovaxin is designed to train each patient's immune system to fight a particular type of white blood cell that is involved in multiple sclerosis. The vaccine is made by drawing blood from a patient and isolating specific types of T-cells. The cells are then expanded and irradiated so they cannot divide and reproduce. Patients take the drug in a series of five injections. The first four are given one month apart, and the fifth is given two months later.